Apellis Pharmaceuticals (APLS) Competitors $24.37 +0.04 (+0.16%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$23.70 -0.68 (-2.77%) As of 08/8/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS vs. QGEN, MRNA, ASND, VTRS, BBIO, VRNA, BPMC, ROIV, GRFS, and LEGNShould you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include QIAGEN (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Apellis Pharmaceuticals vs. Its Competitors QIAGEN Moderna Ascendis Pharma A/S Viatris BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Grifols Legend Biotech Apellis Pharmaceuticals (NASDAQ:APLS) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation. Does the media refer more to APLS or QGEN? In the previous week, Apellis Pharmaceuticals had 2 more articles in the media than QIAGEN. MarketBeat recorded 23 mentions for Apellis Pharmaceuticals and 21 mentions for QIAGEN. QIAGEN's average media sentiment score of 0.77 beat Apellis Pharmaceuticals' score of 0.75 indicating that QIAGEN is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apellis Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive QIAGEN 5 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in APLS or QGEN? 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 70.0% of QIAGEN shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 9.0% of QIAGEN shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, APLS or QGEN? Apellis Pharmaceuticals has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Do analysts prefer APLS or QGEN? Apellis Pharmaceuticals currently has a consensus price target of $34.12, indicating a potential upside of 40.00%. QIAGEN has a consensus price target of $49.69, indicating a potential upside of 3.47%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than QIAGEN.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.58QIAGEN 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27 Which has better earnings & valuation, APLS or QGEN? QIAGEN has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApellis Pharmaceuticals$781.37M3.94-$197.88M-$1.82-13.39QIAGEN$1.98B5.40$83.59M$1.6928.41 Is APLS or QGEN more profitable? QIAGEN has a net margin of 18.30% compared to Apellis Pharmaceuticals' net margin of -30.24%. QIAGEN's return on equity of 14.77% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Apellis Pharmaceuticals-30.24% -116.09% -26.72% QIAGEN 18.30%14.77%8.86% SummaryQIAGEN beats Apellis Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLS vs. The Competition Export to ExcelMetricApellis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.07B$2.97B$5.44B$9.61BDividend YieldN/A2.46%4.61%4.14%P/E Ratio-13.3916.9029.7624.84Price / Sales3.94313.57449.1298.65Price / CashN/A41.8536.4258.36Price / Book19.657.318.185.64Net Income-$197.88M-$54.43M$3.26B$265.68M7 Day Performance6.19%0.00%6.88%4.95%1 Month Performance26.86%1.33%1.00%0.83%1 Year Performance-34.15%8.64%28.85%22.18% Apellis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLSApellis Pharmaceuticals4.701 of 5 stars$24.37+0.2%$34.12+40.0%-35.3%$3.07B$781.37M-13.39770QGENQIAGEN3.5566 of 5 stars$50.27+0.7%$49.40-1.7%+8.5%$11.10B$1.98B21.605,765News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionMRNAModerna4.3236 of 5 stars$27.64+0.1%$45.61+65.0%-69.0%$10.68B$3.24B0.005,800Earnings ReportAnalyst RevisionASNDAscendis Pharma A/S3.4182 of 5 stars$184.15+5.5%$223.67+21.5%+52.0%$10.67B$393.54M0.001,017Trending NewsEarnings ReportAnalyst ForecastGap UpVTRSViatris1.7969 of 5 stars$8.94+1.5%$10.40+16.3%-19.8%$10.34B$14.74B3.5532,000Trending NewsEarnings ReportDividend AnnouncementAnalyst UpgradeShort Interest ↑BBIOBridgeBio Pharma4.7246 of 5 stars$47.75+0.8%$61.18+28.1%+90.3%$8.99B$221.90M0.00400Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share1.5812 of 5 stars$105.47+0.3%$109.00+3.3%+387.4%$8.95B$42.28M0.0030Positive NewsEarnings ReportInsider TradeBPMCBlueprint Medicines0.6825 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.3486 of 5 stars$11.51+1.8%$16.50+43.4%+5.9%$7.69B$29.05M0.00860GRFSGrifols3.2625 of 5 stars$10.72-0.6%$10.30-3.9%+44.4%$7.41B$7.81B0.0023,822Analyst ForecastLEGNLegend Biotech3.832 of 5 stars$38.45-0.9%$73.33+90.7%-35.0%$7.13B$627.24M0.002,609News CoveragePositive NewsUpcoming EarningsAnalyst Revision Related Companies and Tools Related Companies QGEN Alternatives MRNA Alternatives ASND Alternatives VTRS Alternatives BBIO Alternatives VRNA Alternatives BPMC Alternatives ROIV Alternatives GRFS Alternatives LEGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLS) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLS Stock Alerts